سعر لانجوتروبيوم 250مكجم/مل 20 وحدة فيال مفردة للاستنشاق 250 مكجم/1 مل 2024

Lungotropium 250 mcg/1 ml nebuliser solution (20 single-dose vials) by Eva Pharma (Egypt): ipratropium bromide, an inhaled anticholinergic bronchodilator.

• Reversible airway obstruction associated with chronic obstructive pulmonary disease (COPD).Egyptian Drug Authority (EDA)
• With inhaled beta2-agonists, reversible airway obstruction as in acute and chronic asthma.Egyptian Drug Authority (EDA)
• Maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema (alone or with other bronchodilators).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Over 10%: bronchitis (10-23%), COPD exacerbation (8-23%), sinusitis (1-11%). 1-10%: headache, dizziness, dyspepsia, nausea, dry mouth, dysgeusia, urinary tract infection, back pain, dyspnoea, flu-like symptoms, cough, rhinitis, upper respiratory tract infection.General active-ingredient information · Egyptian Drug Authority (EDA)

• Hypersensitivity to ipratropium, atropine or any of the excipients.General active-ingredient information · Egyptian Drug Authority (EDA)
• Known hypersensitivity to ipratropium bromide or to atropine and its derivatives.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Anaphylaxis and other hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, oropharyngeal oedema): discontinue immediately and consider alternatives.General active-ingredient information · Egyptian Drug Authority (EDA)
• Paradoxical bronchospasm may develop; discontinue immediately and treat with a fast-acting inhaled bronchodilator.General active-ingredient information · Egyptian Drug Authority (EDA)
• May cause dizziness and blurred vision; caution with driving or operating machinery.General active-ingredient information · Egyptian Drug Authority (EDA)

• Anticholinergic agentsRisk X: avoid combination.Egyptian Drug Authority (EDA)
• LoxapineRisk X: avoid combination.Egyptian Drug Authority (EDA)
• MethacholineRisk D: consider therapy modification.Egyptian Drug Authority (EDA)

• No human data; give during pregnancy only if the possible benefit outweighs the potential risk to the fetus.General active-ingredient information · Egyptian Drug Authority (EDA)
• No human data; ipratropium is unlikely to reach the infant to an important extent, but caution is advised in nursing mothers.General active-ingredient information · Egyptian Drug Authority (EDA)

English text not available for this section.